List of Excipients in Branded Drug IHEEZO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Harrow Eye LLC	IHEEZO	chloroprocaine hydrochloride ophthalmic gel	82667-300	HYDROCHLORIC ACID
Harrow Eye LLC	IHEEZO	chloroprocaine hydrochloride ophthalmic gel	82667-300	HYDROXYETHYL CELLULOSE
Harrow Eye LLC	IHEEZO	chloroprocaine hydrochloride ophthalmic gel	82667-300	WATER

IHEEZO Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

IHEEZO is a preservative-free, single-dose ophthalmic gel containing chloroprocaine hydrochloride 3% for ocular surface anesthesia during ophthalmic procedures. Its commercial differentiation depends less on the active ingredient, which is long established, and more on formulation performance, dosing convenience, ocular tolerability, packaging, and procedure-level economics. The strongest opportunities are preservative-free delivery, reduced operating-room preparation, predictable anesthesia for office-based procedures, and differentiated unit-dose systems.

What is IHEEZO and how is it formulated?

IHEEZO contains chloroprocaine hydrochloride at 30 mg/mL in an ophthalmic gel. Harrow received U.S. Food and Drug Administration approval in September 2022 under NDA 214581. The product is indicated for topical ocular anesthesia during ophthalmic procedures. The labeled administration is one to two drops applied to the affected eye, with repeat administration when needed according to the prescribing information. [1]

The publicly disclosed inactive ingredients are:

Formulation element	Publicly identified role
Sodium chloride	Tonicity adjustment
Hydrochloric acid and/or sodium hydroxide	pH adjustment
Water for injection	Aqueous vehicle
Gel-forming system	Provides residence time and the product’s ophthalmic gel dosage form

The prescribing information identifies the product as preservative-free and supplied in a single-dose container. [1] That combination is commercially relevant because ophthalmic anesthetics are often used in procedure rooms where contamination control, rapid preparation, and minimizing preservative exposure affect purchasing decisions.

What excipients are most important in IHEEZO?

The core excipient strategy has four functional objectives:

1. Maintain chloroprocaine chemical stability.
2. Achieve ocular tolerability at a clinically effective concentration.
3. Keep the gel on the ocular surface long enough to provide anesthesia.
4. Permit sterile, single-use packaging without preservatives.

The gel matrix is the key differentiator. A conventional ophthalmic solution can drain rapidly through the nasolacrimal system, whereas a gel can increase ocular surface residence time. The tradeoff is that excessive viscosity can cause blurred vision, delayed clearance, dosing inconsistency, or patient discomfort.

Sodium chloride provides a straightforward route to controlling osmolality. The formulation must remain sufficiently close to physiologic tonicity to reduce stinging and reflex tearing, while also accommodating the high chloroprocaine hydrochloride load. The pH adjustment system must balance drug stability against ocular comfort. Strongly acidic or alkaline products can create immediate tolerability problems even when the active ingredient is effective.

How does the excipient strategy create commercial value?

IHEEZO’s excipients support a product-level value proposition rather than a new pharmacologic mechanism.

Preservative-free positioning

Preservative-free ophthalmic products have a commercial advantage in repeated-use clinical environments and in procedures involving compromised ocular surfaces. Benzalkonium chloride and other preservatives can cause epithelial toxicity or irritation, particularly with repeated exposure. IHEEZO avoids that issue through single-dose packaging rather than through a multidose preservative system. [1]

This strategy increases packaging cost and may create waste from unused product. The economic case depends on whether the product reduces preparation time, limits contamination risk, or improves procedural workflow enough to offset the higher per-dose price.

Gel residence time

The gel dosage form can support a higher-value positioning than conventional chloroprocaine or proparacaine solutions if it provides adequate anesthesia with fewer applications. The relevant commercial metrics are:

• Number of applications per procedure
• Time from administration to procedural start
• Duration of anesthesia
• Need for supplemental anesthetic
• Incidence of stinging or blurred vision
• Product waste per procedure
• Compatibility with standard ophthalmic workflow

A gel that requires fewer administrations may be attractive in cataract surgery, intravitreal injection, laser procedures, and minor anterior-segment interventions. The product must still maintain adequate optical clarity and predictable drop size.

Unit-dose delivery

Single-dose packaging protects the preservative-free claim and creates a clean procedural workflow. It also creates potential opportunities for improvements in:

• Container ergonomics
• Drop-size consistency
• Low-dead-volume packaging
• Easy opening with gloves
• Color coding
• Tamper evidence
• Integration with ophthalmic procedure trays

Packaging improvements may be protected separately from the drug composition and could support lifecycle management even if composition claims become difficult to enforce.

What formulations could compete with or improve on IHEEZO?

Potential follow-on formulations fall into four categories.

Formulation concept	Commercial objective	Main technical barrier
Lower-viscosity gel	Reduce blurred vision and improve comfort	Shorter residence time
Higher-viscosity gel	Extend anesthesia and reduce redosing	Greater visual disturbance and dosing variability
Mucoadhesive gel	Improve retention on the ocular surface	Irritation, difficult clearance, manufacturing complexity
Preservative-free multidose system	Reduce packaging waste	Sterility maintenance and container-device performance

A follow-on product could also target a lower concentration, a different rheology profile, or a modified drop volume. The strongest opportunities are likely to involve measurable procedural benefits rather than minor excipient substitutions.

A formulation that simply replaces one buffer or tonicity agent may have limited commercial value unless it improves stability, comfort, shelf life, or container compatibility. In pharmaceutical litigation, excipient changes also require careful analysis because a different inactive ingredient may avoid a composition claim while still infringing method, concentration, dosage-form, or packaging claims.

What patents protect IHEEZO and how strong is the patent estate?

IHEEZO is based on an old active ingredient, so the principal intellectual-property value is likely concentrated in formulation, dosage form, use, manufacturing, and packaging claims rather than chloroprocaine itself.

The relevant patent categories are:

Formulation patents

Potential claims may cover:

• Chloroprocaine hydrochloride concentration
• Ophthalmic gel composition
• pH and osmolality ranges
• Viscosity or rheological parameters
• Preservative-free composition
• Stability characteristics
• Specific excipient combinations

Formulation claims are strongest when they recite measurable product attributes that are difficult to design around without losing the commercial advantage. Broad claims to chloroprocaine in an ophthalmic vehicle are more vulnerable to prior-art challenges because chloroprocaine ophthalmic use predates IHEEZO.

Method-of-use patents

Method claims may cover administration during particular ophthalmic procedures, dosing intervals, or anesthesia protocols. They can delay or complicate generic substitution where the label includes a patented use. Their value is limited if physicians can prescribe the generic for an unclaimed use or if the generic seeks a label carve-out.

Manufacturing and packaging patents

Manufacturing claims could address sterile gel production, filling, container closure, or stability control. These claims may be commercially useful where the product requires specialized aseptic processing or a specific container system. They are less likely to block all generic competition if an alternative manufacturing process is available.

Orange Book status and patent expiration

FDA approval alone does not establish the full patent term or the scope of any listed patents. The relevant data sources are the current FDA Orange Book listing for NDA 214581, FDA patent submissions, and the underlying U.S. patent records. [2,3]

Because chloroprocaine is an established active ingredient, IHEEZO should not be treated as having five-year new-chemical-entity exclusivity. Any regulatory exclusivity would depend on the specific approval basis and qualifying clinical investigations. The commercial protection is therefore expected to depend primarily on formulation and use patents, regulatory exclusivity if listed, and execution in the ophthalmic market.

When does IHEEZO lose exclusivity?

There is no commercially meaningful assumption that IHEEZO has a long NCE exclusivity period. The critical dates are:

Event	Date or status
FDA approval	September 2022
NCE exclusivity	Not expected for chloroprocaine
Three-year exclusivity	Requires confirmation in the current Orange Book
Listed patent expiry	Requires patent-by-patent confirmation
First potential ANDA challenge	Dependent on listed patents and generic filing strategy

A generic company could pursue a Paragraph IV certification against listed patents or a Paragraph III certification against patents it accepts. If no relevant patent is listed, an ANDA applicant could proceed under ordinary approval timing, subject to FDA review and any applicable exclusivity.

What Paragraph IV challenges and generic entry risks exist?

A generic version of IHEEZO would most likely use the 505(j) abbreviated new drug application pathway if the applicant can demonstrate pharmaceutical equivalence and bioequivalence to the reference product. [4]

The key regulatory challenges are likely to include:

• Demonstrating equivalence for a gel rather than a simple ophthalmic solution
• Matching chloroprocaine concentration and dosage form
• Characterizing viscosity, rheology, pH, osmolality, and droplet size
• Establishing comparable in vitro performance
• Addressing local ocular tolerability
• Reproducing sterile single-dose packaging
• Determining whether clinical endpoint studies are necessary

A Paragraph IV challenge would be commercially credible if the patent estate depends on narrow formulation claims. The generic applicant could attempt to design around:

• A specific viscosity range
• A particular polymer or excipient
• A narrow pH window
• Packaging limitations
• Procedure-specific method claims

The most important generic-entry risk is not necessarily an exact copy of the commercial formulation. A lower-cost ophthalmic gel with comparable performance could pressure pricing even if it does not reproduce every excipient.

Is biosimilar risk relevant to IHEEZO?

No. IHEEZO contains chloroprocaine hydrochloride, a chemically synthesized small molecule. It is not a biologic and is not subject to the biosimilar pathway under the Public Health Service Act. Competition would arise through generic drug approval, 505(b)(2) development, compounding, or alternative ophthalmic anesthetics.

A 505(b)(2) product could be relevant if it changes the dosage form, concentration, delivery device, or clinical use and relies partly on existing FDA findings. That route may be more suitable than a conventional ANDA for a materially different gel or device combination. [4]

Which products compete with IHEEZO?

IHEEZO competes with established topical ophthalmic anesthetics and procedural anesthesia practices.

Product or approach	Active ingredient or basis	Competitive position
IHEEZO	Chloroprocaine HCl 3% gel	Preservative-free, single-dose gel
Proparacaine ophthalmic solution	Proparacaine HCl	Familiar, low-cost topical anesthetic
Tetracaine ophthalmic solution	Tetracaine HCl	Established anesthetic, often used in procedure settings
Lidocaine ophthalmic products	Lidocaine	Alternative topical anesthetic, depending on formulation
Compounded chloroprocaine	Chloroprocaine	Potential price competition, but quality and availability vary
Injectable local anesthetic techniques	Various agents	More invasive, generally reserved for selected procedures

IHEEZO’s commercial opportunity is strongest where physicians value workflow, preservative-free use, and predictable local anesthesia over the lowest acquisition cost.

What licensing and commercial opportunities exist?

The principal commercial opportunities are:

Ophthalmology procedure partnerships

Harrow can pursue purchasing agreements with ambulatory surgery centers, cataract networks, retina practices, and office-based ophthalmology groups. Contracting should focus on total procedure cost rather than unit price alone.

Procedure-tray integration

IHEEZO could be included in standardized kits for cataract, intravitreal, and laser procedures. Tray integration can improve utilization and create switching costs, although the product must meet volume, packaging, and supply-reliability requirements.

Device and packaging licensing

A lower-dead-volume applicator or more ergonomic single-dose container could support a separate licensing program. Device improvements may be especially valuable if they reduce product waste or improve dosing consistency.

Geographic expansion

The formulation has potential outside the United States, but market entry would require country-specific assessment of chloroprocaine status, ophthalmic gel classification, preservative requirements, sterile packaging standards, and reimbursement. European and Asian markets may have different acceptance criteria for unit-dose gels and different reference-product requirements.

Veterinary ophthalmology

Veterinary use is a possible adjacent market for topical ocular anesthesia, but it would require separate regulatory, clinical, and commercial analysis. Human-label success does not automatically establish veterinary approval or market access.

What revenue exposure is associated with IHEEZO?

IHEEZO revenue is exposed to four variables:

1. Procedure volume, particularly cataract and intravitreal procedures.
2. Adoption relative to low-cost anesthetic drops.
3. Net price after hospital and group-practice discounts.
4. Timing and scope of generic or 505(b)(2) competition.

The product’s opportunity is greater in settings where ophthalmologists perform high procedure volumes and can capture operational savings. The largest risk is a price-driven substitution toward proparacaine or tetracaine if clinical differentiation is not supported by measurable workflow or tolerability benefits.

Key Takeaways

• IHEEZO’s value is driven by its preservative-free, single-dose ophthalmic gel formulation, not by a new active ingredient.
• The gel matrix, pH, osmolality, viscosity, sterility, and packaging are the principal excipient and product-development levers.
• Formulation and method-of-use patents are more important than active-ingredient patents.
• IHEEZO is not subject to biosimilar competition; generic and 505(b)(2) pathways are the relevant threats.
• A credible generic challenge would focus on formulation equivalence, design-around options, and any Orange Book-listed patents.
• Commercial expansion is most attractive in cataract surgery, intravitreal injection, laser procedures, office-based ophthalmology, and standardized procedure kits.
• The principal market risk is substitution by inexpensive proparacaine or tetracaine products.

FAQs

Can IHEEZO be reformulated as a multidose preservative-free product?

Yes, but the container-closure system would need to maintain sterility after repeated access. That requirement makes multidose development more complex than IHEEZO’s current single-dose format.

Would a lower-viscosity IHEEZO version be commercially attractive?

Potentially. A lower-viscosity formulation could reduce blurred vision and improve comfort, but it would need to preserve adequate ocular residence time and anesthesia duration.

Can a generic use different excipients from IHEEZO?

Possibly. An ANDA applicant generally must demonstrate pharmaceutical equivalence and bioequivalence, but it may use different inactive ingredients when permitted by FDA requirements and when the differences do not affect safety, efficacy, or performance.

Is chloroprocaine hydrochloride difficult to manufacture in an ophthalmic gel?

The active ingredient is established, but sterile production of a concentrated ophthalmic gel requires control of pH, viscosity, microbial quality, filling accuracy, container compatibility, and stability.

Does preservative-free packaging increase IHEEZO’s commercial moat?

It can. The advantage is strongest when the packaging improves contamination control and workflow without creating excessive waste or administration difficulty.

References

1. U.S. Food and Drug Administration. (2022). IHEEZO (chloroprocaine hydrochloride ophthalmic gel) prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Patent and Trademark Office. (2024). Patent Center and Patent Public Search.
4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application process and 505(b)(2) applications.